Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

Breast cancer (BC) is the most common malignancy in women. It is classified into a few
major molecular subtypes according to hormone and growth factor receptor expression …

Although long non-coding RNAs (lncRNAs) predominately reside in the nucleus and exert
their functions in many biological processes, their potential involvement in cytoplasmic …

An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer
cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with …

Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal …

Introduction: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer
associated with poor prognosis and limited treatment options. Validated prognostic and …

Patients with breast cancer along with metastatic estrogen and progesterone receptor
(ER/PR)-and human epidermal growth factor receptor 2 (HER2)-negative tumors are …

Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The
disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in …

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by
aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still …

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often
associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate …